← Back to Clinical Trials
Recruiting NCT06326879

NCT06326879 A Comparative Study Between Early Onset Colorectal Cancer and Late Onset Colorectal Cancer Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06326879
Status Recruiting
Phase
Sponsor Istituto Clinico Humanitas
Condition Colorectal Cancer
Study Type OBSERVATIONAL
Enrollment 340 participants
Start Date 2023-11-30
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
No intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 340 participants in total. It began in 2023-11-30 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to investigate the clinical, socioeconomic, behavioral, genetic, and molecular factors characterizing Early Onset Colorectal Cancer (EOCRC) patients compared with Late Onset Colorectal Cancer (LOCRC) patients

Eligibility Criteria

Inclusion Criteria: * Patients aged more than 18 years old at the time of inclusion. * Patients with a proven diagnosis of colorectal adenocarcinoma, as reported by the staging histological biopsies. * Patients with a preoperative staging I-III. * Patients scheduled for elective curative colorectal resection. * Patients with rectal cancer who underwent neoadjuvant therapy can be included in the study. * Patients able and willing to comply with the protocol requirements (samples' collection and questionnaires' compilation). Exclusion Criteria: * Patients with metastatic disease at diagnosis. * Patients requiring an emergent procedure. * Patients undergoing palliative surgery (for example, fecal diversion). * Patients with a surgical indication for benign lesions (for example, adenoma or dysplasia). * Patients with an intraoperative finding of a lesion other than adenocarcinoma will be withdrawn from the study. * Patients with an intraoperative finding of distal metastasis or peritoneal carcinosis will be withdrawn from the study. * Patients with a concomitant diagnosis of Inflammatory Bowel Disease. * Patients with a known genetic syndrome (for example, Lynch syndrome or Familial Adenomatous Polyposis).

Contact & Investigator

Central Contact

Annalisa Maroli, PhD

✉ colorapp@humanitas.it

📞 02 8224 7776

Principal Investigator

Antonino Spinelli, MD, PhD

PRINCIPAL INVESTIGATOR

IRCCS Huamanitas Research Hospital

Frequently Asked Questions

Who can join the NCT06326879 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06326879 currently recruiting?

Yes, NCT06326879 is actively recruiting participants. Contact the research team at colorapp@humanitas.it for enrollment information.

Where is the NCT06326879 trial being conducted?

This trial is being conducted at Rozzano, Italy.

Who is sponsoring the NCT06326879 clinical trial?

NCT06326879 is sponsored by Istituto Clinico Humanitas. The principal investigator is Antonino Spinelli, MD, PhD at IRCCS Huamanitas Research Hospital. The trial plans to enroll 340 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology